Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches[1] and for short term prevention of menstrual migraine.[2] The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[3]
Clinical data | |
---|---|
Trade names | Frova |
Other names | 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide (6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide |
AHFS/Drugs.com | Monograph |
MedlinePlus | a604013 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 20–30% |
Metabolism | Hepatic |
Elimination half-life | 26 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C14H17N3O |
Molar mass | 243.310 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Frovatriptan is used in the treatment of migraine.
It is available as 2.5 mg tablets.
Frovatriptan should not be given to patients with:
Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.
Frovatriptan is a serotonin receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites. Frovatriptan inhibits excessive dilation of arteries that supply blood to the head.
Frovatriptan has a terminal elimination half-life of approximately 26 hours, making it the longest within its class.[4]
Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006.[5]